The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
Narayanan to lead SeQuent through next phase of consolidation and growth
Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and commercialization
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
It is the first monoclonal antibody drug for use in any animal species
The new plant at Slovenská ?up?a site in Slovakia is scheduled to come on stream in two years
The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes including cell growth and survival
The companies were evaluated via a comprehensive, in-depth assessment process that included a sustainability framework of 300 points each for – Purpose, Partnership, Planet and People
The stability is led by healthy demand in the domestic and emerging markets
Danny Bar-Zohar will become Global Head of R&D and Joern-Peter Halle will become Chief Strategy Officer
Subscribe To Our Newsletter & Stay Updated
